Tocilizumab in Systemic Juvenile Idiopathic Arthritis in a Real-World Clinical Setting: Results From 1 Year of Postmarketing Surveillance Follow-Up of 417 Patients in Japan
Annals of the Rheumatic Diseases - United Kingdom
doi 10.1136/annrheumdis-2015-207818
Full Text
Open PDFAbstract
Available in full text
Date
December 7, 2015
Authors
Publisher
BMJ